Enhanced Oncolytic Virus System with AI-Powered Personalized Cancer Therapy
Legal Citation
Summary of the Inventive Concept
A novel system integrating oncolytic viruses with advanced technologies like AI, IoT, blockchain, and graphene-based materials to provide personalized, effective, and secure cancer treatment.
Background and Problem Solved
Despite the progress in oncolytic virus development, limitations remain in terms of optimal dosing regimens, patient data management, and treatment efficacy monitoring. The present inventive concept addresses these challenges by synergistically combining the patented oncolytic virus with cutting-edge technologies.
Detailed Description of the Inventive Concept
The enhanced oncolytic virus system comprises a recombinant oncolytic virus with a truncated fragment of HSV1-TK, a machine learning module for predicting optimal dosing regimens, a blockchain-based patient data management system, a graphene-based material for viral stability and delivery, and an IoT sensor module for real-time monitoring of tumor response. The system enables personalized cancer therapy by leveraging AI-driven predictions, secure patient data management, and targeted treatment administration.
Novelty and Inventive Step
The new claims introduce a synergistic combination of distinct technologies, providing a non-obvious solution that significantly improves the safety and anticancer effect of oncolytic viruses. The integration of AI, blockchain, IoT, and graphene-based materials with the patented oncolytic virus constitutes a novel and inventive step beyond the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different AI algorithms, blockchain platforms, or graphene-based materials. Variations could involve integrating the oncolytic virus with other advanced technologies, such as nanotechnology or synthetic biology, to further enhance treatment outcomes.
Potential Commercial Applications and Market
The enhanced oncolytic virus system has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, precision oncology, and targeted therapy. The system's ability to provide secure, effective, and personalized treatment makes it an attractive solution for pharmaceutical companies, hospitals, and research institutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K35/768 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K31/708 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2710/24111 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology, virology, and cancer therapeutics, with expertise in genetic engineering of viruses, personalized medicine, and advanced therapeutic delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in molecular biology or bioengineering, experienced in oncolytic virus design, genetic modification techniques, and interdisciplinary medical technology integration
Obviousness Rationale
A person skilled in the art would recognize that integrating advanced technologies with the core oncolytic virus technology represents a predictable extension of existing cancer treatment strategies. The combination of AI, blockchain, and advanced materials with the established HSV1-TK truncated fragment approach provides a logical progression of personalized cancer therapy techniques. The individual technological components are well-known in the field, and their application to oncolytic virus systems would be considered a routine optimization by a skilled practitioner.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,585 |
|---|---|
| Title | Oncolytic virus improved in safety and anticancer effect |
| Assignee(s) | BIONOXX INC. |